Study Title
PNOC022: A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
Protocol ID
PNOC022
Condition/s
Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent Diffuse Intrinsic Pontine Glioma
Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent WHO Grade III Glioma
WHO Grade III Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent Diffuse Intrinsic Pontine Glioma
Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
Recurrent WHO Grade III Glioma
WHO Grade III Glioma
Diagnosis Stage
Newly diagnosed
Relapsed/Refractory
Relapsed/Refractory
Location
NSW, QLD, VIC, WA, SA, NZ
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Collaborators
Pacific Pediatric Neuro-Oncology Consortium
Links
Trial Status
Open
Sites
Women's and Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
2 Years to 39 Years
International registry ID's
NCT05009992
| Study Title | PNOC022: A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis Post-Radiation Therapy and at Time of Progression |
|---|---|
| Protocol ID | PNOC022 |
| Disease (Sub Disease) | Diffuse Intrinsic Pontine Glioma Diffuse Midline Glioma, H3 K27M-Mutant Recurrent Diffuse Intrinsic Pontine Glioma Recurrent Diffuse Midline Glioma, H3 K27M-Mutant Recurrent WHO Grade III Glioma WHO Grade III Glioma |
| Diagnosis Stage | Newly diagnosed Relapsed/Refractory |
| Location | NSW / QLD / VIC / WA / SA / NZ |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group |
| Collaborators | Pacific Pediatric Neuro-Oncology Consortium |
| Links | https://clinicaltrials.gov/ct2/show/NCT05009992 |
| Trial Status | Open |
| Trial Open Date | 18/08/2022 |
| Sites | Women's and Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 2 Years to 39 Years |
| International registry ID's | NCT05009992 |